Skip to content

Disc Medicine IRON Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
$23.37M+96.1%
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
$2.08M+28.4%
Beam Therapeutics logo
Beam TherapeuticsBEAM
$2.03M+182%
Travere Therapeutics, Inc. logo
Travere Therapeutics, Inc.TVTX
$4.73M+11.5%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$22.59M
PTC Therapeutics logo
PTC TherapeuticsPTCT
$6.4M-59.3%

Other financials

Income statement

See full
Operating income-$69.5M-74.0%
Net income-$63.5M-86.3%
EPS (diluted)-$1.65-61.8%

Balance sheet

See full
Cash & equivalents$88.9M-27.5%
Total debt$31.1M+1.4%
Total equity$688.4M+4.3%
Total assets$750.2M+5.8%

Cash flow

See full
Operating cash flow-$62.2M-50.4%
CapEx--100%
Free cash flow-$62.2M-47.4%

Valuation

See full
Market cap$2.69B+42.2%
Enterprise value$2.63B+46.7%

Returns & leverage

See full
Return on equity-35.8%+41.3pp
Debt / equity0.0×
Current ratio24×-13.6×

Where this comes from

Reported directly by Disc Medicine in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromStockOptionsExercised.

The official record: Disc Medicine’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Disc Medicine's stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Disc Medicine's stock issuance proceeds?
Disc Medicine (IRON) reported stock issuance proceeds of $1.01M in Q1 2026.
How has Disc Medicine's stock issuance proceeds changed year-over-year?
Disc Medicine's stock issuance proceeds increased by 75.7% year-over-year, from $575K to $1.01M.
What does stock issuance proceeds mean?
Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.